通化金马：药在审评过程中出现暂停等情形是新药专业和综合审评过程中的正常状态

Group 1 - The company is currently in the normal review process for its new drug, Amber Batin Akridin Tablets, which has resumed evaluation after a pause [2] - The occurrence of pauses during the review process is a standard part of the professional and comprehensive evaluation of new drugs [2] - The company is actively communicating with the Center for Drug Evaluation (CDE) and responding to relevant materials during this process [2]